粪便胆汁酸与脂肪排泄是肠易激综合征中临床显著腹泻与便秘的生物标志物
研究纳入126名健康志愿者、64例腹泻型肠易激综合征(IBS-D)和30例便秘型肠易激综合征(IBS-C)患者,评估粪便胆汁酸、粪便脂肪及空腹血清C4与FGF19等指标,发现粪便胆汁酸和粪便脂肪是与IBS-D和IBS-C患者显著肠道功能障碍相关的经济、准确的生物标志物。
要点
- 粪便总胆汁酸和初级胆汁酸降低及粪便石胆酸升高可预测粪便重量、频率和稠度下降,AUC>0.82。
- 粪便总胆汁酸、初级胆汁酸和粪便脂肪可预测粪便重量、频率和稠度增加,AUC>0.71。
- 粪便参数预测粪便重量升高的阳性似然比为11.5。
核心结论
- 粪便胆汁酸和粪便脂肪是经济有效且准确的生物标志物,与IBS-D和IBS-C患者中显著的肠道功能障碍相关。
研究设计与样本
- 研究纳入126名健康志愿者(44男/82女,37.5±10.9岁[标准差])、64例IBS-D患者(5男/59女,41.9±12.2岁)和30例IBS-C患者(0男/30女,44.6±10岁),按罗马III标准诊断。
- 评估内容包括经过验证的排便日记中的每日排便频率与稠度(布里斯托粪便性状量表)、48小时粪便总胆汁酸及单个胆汁酸、48小时粪便脂肪与重量、空腹血清C4与FGF19,以及闪烁显像测定的结肠传输。
- 采用多因素logistic回归,基于排便频率、稠度和重量确定临床显著腹泻或便秘的生物标志物。
主要发现
- 所有组间在粪便重量、频率和稠度上存在显著差异;IBS-D与IBS-C之间在48小时结肠传输、粪便脂肪及粪便总胆汁酸和单个胆汁酸上存在差异。
- 粪便总胆汁酸和初级胆汁酸降低及粪便石胆酸升高是粪便重量、频率和稠度下降的显著预测因素,AUC>0.82(敏感性>76%,特异性>72%)。
- 粪便总胆汁酸、初级胆汁酸和粪便脂肪是粪便重量、频率和稠度增加的显著预测因素,AUC>0.71(敏感性>55%,特异性>74%)。
- 粪便参数预测粪便重量升高的阳性似然比为11.5。
关键数值与推荐
- 原文提出,75%准确性和成本<$500可将生物标志物归类为经济有效。
- 粪便总胆汁酸和初级胆汁酸降低及粪便石胆酸升高预测粪便重量、频率和稠度下降:AUC>0.82,敏感性>76%,特异性>72%。
- 粪便总胆汁酸、初级胆汁酸和粪便脂肪预测粪便重量、频率和稠度增加:AUC>0.71,敏感性>55%,特异性>74%。
- 粪便参数预测粪便重量升高的阳性似然比为11.5。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biomarkers in irritable bowel syndrome (IBS) may guide targeted therapy in this multifactorial disease. It has been suggested that 75% accuracy and cost <$500 categorise biomarkers as cost-effective. AIM: To identify differences in faecal bile acids, faecal fat and fasting serum C4 (7a-hydroxy-4-cholesten-3-one) and fibroblast growth factor 19 (FGF19) among patients with IBS-D, IBS-C and healthy controls and to determine accurate, cost-effective biomarkers for clinically relevant diarrhoea and constipation. METHODS: We assessed daily stool frequency and consistency (Bristol Stool Form Scale) from validated bowel diaries, 48 hours total and individual faecal bile acids, 48 hours faecal fat and weight, fasting serum C4 and FGF19, and colonic transit by scintigraphy from healthy volunteers (HV) and patients with IBS-D and IBS-C (Rome III criteria). We utilised multivariate logistic regression to determine biomarkers of clinically significant diarrhoea or constipation based on stool frequency, consistency and weight. RESULTS: Among the 126 HV (44M/82F, 37.5 ± 10.9 years [SD]), 64 IBS-D (5M/59F, 41.9 ± 12.2 years), and 30 IBS-C (0M/30F, 44.6 ± 10 years) patients, there were significant differences between all groups in stool weight, frequency, and consistency; in addition, there were differences in colonic transit at 48 hours, faecal fat, and total and individual faecal bile acids between IBS-D and IBS-C. Reduced total and primary faecal bile acids and increased faecal lithocholic acid were significant predictors of decreased faecal weight, frequency and consistency with AUC > 0.82 (sensitivity >76%, specificity >72%). Total and primary faecal bile acids and faecal fat were significant predictors of increased stool weight, frequency and consistency with AUC > 0.71 (sensitivity >55%, specificity >74%).The faecal parameters had a 11.5 positive likelihood ratio in predicting elevated faecal weight. CONCLUSIONS: Faecal bile acids and faecal fat are cost-effective and accurate biomarkers associated with significant bowel dysfunction among IBS-D and IBS-C patients.
引用
- Vijayvargiya P, Camilleri M, Burton D, et al. Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome. Aliment Pharmacol Ther. 2019. PMID: 30740753. doi:10.1111/apt.15106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。